The effect of diclofenac sodium on bladder detrusor contractility and its clinical implication

Xu, Yaoting; Li, Dujian; Gu, Wei; Li, Wenguang

doi:10.5372/1905-7415.0701.147

Abstract

Background: Overactive bladder symptom (OAB) seriously influences a person’s life including mobility, workrelated activities, sleep, domestic, and sexual life. Many patients with OAB symptoms have insufficient improvement from usual treatment.

Objective: To investigate the effects of Diclofenac Sodium (DS) on bladder detrusor contractility and on the clinical symptoms associated with detrusor over-activity of patients following prostatectomy.

Methods: Bladders dissected from guinea pigs were used to study the effect of DS on uninhibited bladder contractions in vitro. Bladder detrusor contraction was evoked by histamine. The tension of bladder detrusor and the frequency and amplitude of bladder detrusor contraction were measured. In vivo efficacy of DS was then measured in patients after prostatectomy by using the symptom scoring system and by detecting the duration of the efficacy.

Results: DS significantly inhibited the contraction of detrusor evoked by histamine in a dose-dependent manner. The inhibition of bladder detrusor contraction by DS was statistically significantly stronger compared to that by normal saline (NS) and was analogous to that by verapamil in vitro. The total effective rates of DS were a little higher than intravenous verapamil in vivo. The complete remission rate and the mean effect-lasting time of rectal diclofenac were significantly higher than that of intravenous verapamil. No significant side effect was observed in patients with DS treatment.

Conclusion: DS significantly inhibited the contraction of bladder in vivo and in vitro. DS could act as a useful agent for the relief of overactive bladder symptom post-prostatectomy.

References

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61:37-49.10.1016/S0090-4295(02)02243-4
Open DOI Search in Google Scholar Back to article
2. MacDiarmid S, Sandage BW, Jr., Malhotra BK. The effects of reformulation: improved therapeutic index. Curr Urol Rep. 2008; 9:465-71.10.1007/s11934-008-0080-618947511
Open DOI Search in Google Scholar Back to article
3. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 1999; 10:283-9.10.1007/s00192997000310543335
Open DOI Search in Google Scholar Back to article
4. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new nonsteroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res. 1995; 44: 423-33.10.1007/BF017576998564518
Open DOI Search in Google Scholar Back to article
5. Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol. 1999; 128:1121-32.10.1038/sj.bjp.0702897157174410578123
Open DOI Search in Google Scholar Back to article
6. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/ Sumatriptan Migraine Study Group. Cephalalgia. 1999; 19:232-40.10.1046/j.1468-2982.1999.019004232.x10376168
Search in Google Scholar Back to article
7. McNeely W, Goa KL. Diclofenac-potassium in migraine: a review. Drugs. 1999; 57:991-1003.10.2165/00003495-199957060-0001610400409
Open DOI Search in Google Scholar Back to article
8. Karachalios GN, Fotiadou A, Chrisikos N, Karabetsos A, Kehagioglou K. Treatment of acute migraine attack with diclofenac sodium: a double-blind study. Headache. 1992; 32:98-100.10.1111/j.1526-4610.1992.hed3202098.x1551795
Open DOI Search in Google Scholar Back to article
9. Kuznetsova AA, Shakhmatova EI, Prutskova NP, Natochin YV. Possible role of prostaglandins in pathogenesis of nocturnal enuresis in children. Scand J Urol Nephrol. 2000; 34:27-31.10.1080/00365590075001684110757266
Open DOI Search in Google Scholar Back to article
10. Davenport K, Timoney AG, Keeley FX, Jr. Effect of smooth muscle relaxant drugs on proximal human ureteric activity in vivo: a pilot study. Urol Res. 2007; 35:207-13.10.1007/s00240-007-0100-x17530238
Open DOI Search in Google Scholar Back to article
11. Chaignat V, Danuser H, Stoffel MH, Z’brun S, Studer UE, Mevissen M. Effects of a non-selective COX inhibitor and selective COX-2 inhibitors on contractility of human and porcine ureters in vitro and in vivo. Br J Pharmacol. 2008; 154:1297-307.10.1038/bjp.2008.193
Open DOI Search in Google Scholar Back to article
12. Badawi JK, Li H, Langbein S, Kwon ST, Kamp S, Bross S. Inhibitory effects of L- and T-type calcium antagonists on contractions of human detrusor muscle. Eur J Clin Pharmacol. 2006; 62:347-54.10.1007/s00228-006-0100-8
Open DOI Search in Google Scholar Back to article
13. Roosen A, Wu C, Sui G, Chowdhury RA, Patel PM, Fry CH. Characteristics of spontaneous activity in the bladder trigone. Eur Urol. 2009; 56:346-53.10.1016/j.eururo.2008.06.048
Open DOI Search in Google Scholar Back to article
14. Batislam E, Nuhoglu B, Peskircioglu L, Emir L, Uygur C, Germiyanoglu C, et al. A prostaglandin synthesis inhibitor, diclofenac sodium in the treatment of primary nocturnal enuresis. Acta Urol Belg. 1995; 63:35-8.
Search in Google Scholar Back to article
15. Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract. 2009; 63:1177-91.10.1111/j.1742-1241.2009.02078.x
Open DOI Search in Google Scholar Back to article
16. Andersson KE, Appell R, Cardozo LD, Chapple C, Drutz HP, Finkbeiner AE, et al. The pharmacological treatment of urinary incontinence. BJU Int. 1999; 84: 923-47.10.1046/j.1464-410x.1999.00397.x
Open DOI Search in Google Scholar Back to article
17. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003; 326:841-4.10.1136/bmj.326.7394.841
Open DOI Search in Google Scholar Back to article
18. Roshani A, Falahatkar S, Khosropanah I, Roshan ZA, Zarkami T, Palizkar M, et al. Assessment of clinical efficacy of intranasal desmopressin spray and diclofenac sodium suppository in treatment of renal colic versus diclofenac sodium alone. Urology. 2010; 75:540-2.10.1016/j.urology.2008.05.053
Open DOI Search in Google Scholar Back to article
19. Iselin CE, Alm P, Schaad NC, Larsson B, Graber P, Andersson KE. Nitric oxide inhibits contraction of isolated pig ureteral smooth muscle. J Urol. 1996; 155: 763-7.10.1016/S0022-5347(01)66517-0
Open DOI Search in Google Scholar Back to article
20. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87:760-6.10.1046/j.1464-410x.2001.02228.x11412210
Open DOI Search in Google Scholar Back to article
21. Stewart W, Herzog R, Wein A. The prevalence and impact of overactive bladder in the U.S.: results from the NOBLE program. Neurourol Urodyn. 2001; 20: 406-8.
Search in Google Scholar Back to article
22. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20:327-3610.1007/s00345-002-0301-412811491
Search in Google Scholar Back to article

The effect of diclofenac sodium on bladder detrusor contractility and its clinical implication

Abstract

Paradigm

My account